- PhD - Experimental Pathology/Epidemiology, University of Buffalo and Roswell Park Cancer Institute
- MS - Epidemiology, University of Buffalo
- BS - Biology, University of Binghamton
- Prediction models for cancer outcomes
- Benefit/risk indices for oncology drugs
- Clinical, epidemiologic, and pharmacogenomic factors related to cancer treatment outcomes
- Cannabis and cancer outcomes
Andrew N. Freedman, PhD, FISPE, is the chief of the Epidemiology and Genomics Research Program's (EGRP) Clinical and Translational Epidemiology Branch (CTEB). He oversees EGRP's research portfolio and initiatives that focus on factors that influence cancer progression, recurrence, new primary cancers, and survival and other treatment outcomes.
In 1997, Dr. Freedman joined NCI's Division of Cancer Control and Population Sciences (DCCPS) as a molecular epidemiologist in the Applied Research Program's (ARP) Risk Factor Monitoring and Methods Branch. He developed and supported a program of research in cancer risk prediction, genetic susceptibility testing, pharmacoepidemiology and pharmacogenomics, and managed research contracts, interagency and cooperative agreements, and a grant portfolio pertaining to these research areas. Dr. Freedman also directed multidisciplinary molecular, clinical, and translational epidemiology studies within the HMO Cancer Research Network (CRN); Department of Veterans Affairs medical system; NCI's Surveillance, Epidemiology, and End Results (SEER) Program; and the NIH-AARP Diet and Health Study. He is internationally recognized for his work in molecular cancer epidemiology, cancer risk prediction, pharmacoepidemiology, and the delivery of precision oncology.
In the areas of pharmacoepidemiology and pharmacogenomics, Dr. Freedman has developed research collaborations with several NIH Institutes and Centers and other agencies within the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA). He was formerly Chair of the Trans-NCI Pharmacoepidemiology and Pharmacogenomics Working Group, and he represented NCI on the Trans-NIH Pharmacogenomics Working Group and the National Academy of Medicine Roundtable on Genomics and Precision Health. Dr. Freedman currently co-chairs NCI’s Cannabis and Cancer Research Interest Group (CCRIG), leading basic, clinical, and population sciences initiatives related to cannabis and cancer outcomes.
Before joining DCCPS, Dr. Freedman was a postdoctoral research fellow in the Genetic Epidemiology Branch of NCI's Division of Cancer Epidemiology and Genetics (DCEG).
See listings of articles and other publications authored by Dr. Freedman in PubMed.